DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Malarone (Atovaquone / Proguanil Hydrochloride) - Published Studies

 
 



Malarone Related Published Studies

Well-designed clinical trials related to Malarone (Atovaquone / Proguanil)

Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers. [2006.09]

Atovaquone-proguanil for treating uncomplicated malaria. [2005.10.19]

A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. [2005.09.01]

Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. [2005.08]

Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions. [2005.07]

A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria. [2005.02]

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. [2004.06.15]

CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. [2004.02]

Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. [2003.12.01]

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. [2002.12.15]

Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. [2002.11.15]

Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. [2002.11.01]

Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. [2002.10.01]

Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. [2002.09]

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. [2001.10.01]

Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. [2001.07]

Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. [2001.04]

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. [2000.12.02]

Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. [2000.11]

Absence of an interaction between artesunate and atovaquone--proguanil. [1999.08]

Lack of a pharmacokinetic interaction between atovaquone and proguanil. [1999.06]

Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. [1999.06]

Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. [1999.05]

Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. [1999.05]

A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. [1999.04]

Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. [1999.04]

Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. [1998.09]

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. [1998.03.07]

Atovaquone and proguanil for the treatment of malaria in Brazil. [1997.06]

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. [1997.05]

Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. [1996.11]

Atovaquone and proguanil for Plasmodium falciparum malaria. [1996.06.01]

Well-designed clinical trials possibly related to Malarone (Atovaquone / Proguanil)

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. [2008.09.16]

Folic acid treatment of Zambian children with moderate to severe malaria anemia. [2006.06]

Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. [2003.11.08]

Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. [2001.12.15]

Other research related to Malarone (Atovaquone / Proguanil)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. [2011.05.21]

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. [2010.05.15]

Plasmodium relictum (lineage P-SGS1): Further observation of effects on experimentally infected passeriform birds, with remarks on treatment with Malarone. [2009.10]

Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. [2008.11.20]

Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride. [2008.07]

Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. [2008.05]

In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand. [2008.01.28]

A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. [2007.11]

Relapsing vivax malaria after 6 months of daily atovaquone/proguanil in Afghanistan: the case for expanded use of primaquine as a causal prophylactic. [2007.11]

A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. [2007.09.10]

Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. [2007.04]

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. [2007.03]

Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil. [2007.03]

Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). [2007.02]

A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children. [2006.11]

Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. [2006.11]

Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. [2006.01]

Atovaquone/proguanil for the prophylaxis and treatment of malaria. [2005.12]

The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. [2005.09]

Acute hepatitis and atovaquone/proguanil. [2005.09]

Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. [2005.04]

Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. [2004.11.01]

Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark. [2004.07]

Quinine-resistant severe falciparum malaria effectively treated with atovaquone and proguanil hydrochloride combination therapy. [2004.07]

Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. [2004.06.08]

Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. [2004.03]

Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis. [2003.11]

The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. [2003.10]

Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam. [2003.09]

Atovaquone-proguanil for prophylaxis and treatment of malaria. [2003.09]

Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. [2003.09]

Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. [2003.08.01]

Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis. [2003.07.01]

The impact of Malarone and primaquine on psychomotor performance. [2003.07]

The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. [2003.05]

Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. [2003.05]

The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. [2003.05]

Atovaquone/proguanil: the need for family protection. [2003.05]

Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. [2003.03.19]

[Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil] [2003.02.15]

Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria. [2003]

Atovaquone/proguanil resistance in Africa: a case report. [2003]

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. [2003]

[Value of malarone in therapy of malaria tropica] [2002.08.15]

Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. [2002.04]

Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. [2002.02.08]

A public-private partnership for malaria control: lessons from the Malarone Donation Programme. [2002]

[What is the value of the combination atovaquone-proguanil for the clinician?] [2002]

[Experience with the combination atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria--report of 112 cases] [2002]

[Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers] [2002]

[Mechanism of action of antimalarials. Value of combined atovaquone/proguanil] [2002]

A political analysis of corporate drug donations: the example of Malarone in Kenya. [2001.06]

[Atovaquone/proguanil. Prophylaxis and treatment of malaria] [2000.07.31]

Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil). [2000.07]

The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine. [2000.01]

Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. [1999.11]

Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. [1999.04]

Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. [1998.03]

Malarone-donation programme in Africa. [1997.11.29]

Antimalaria activity of the triple combination of proguanil, atovaquone and dapsone. [1997.09.30]

Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. [1996.07]

Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. [1996.06]

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. [1996.01]

Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. [1995.04]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012